Validating the positivity thresholds of drug‐tolerant anti‐infliximab and anti‐adalimumab antibody assays

When used proactively, drug‐tolerant anti‐tumour necrosis factor (TNF) antibody assays provide early opportunity to suppress immunogenicity.

[1]  P. Irving,et al.  New role for azathioprine in case of switching anti-TNFs in IBD , 2020, Gut.

[2]  B. Flourié,et al.  Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial , 2020, Gut.

[3]  S. Shen-Orr,et al.  Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-drug Antibodies. , 2019, Gastroenterology.

[4]  J. Barrett,et al.  HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. , 2019, Gastroenterology.

[5]  B. Weiss,et al.  Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn's Disease Compared with Reactive Monitoring. , 2019, Gastroenterology.

[6]  M. Parkes,et al.  Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. , 2019, The lancet. Gastroenterology & hepatology.

[7]  E. Lázár-Molnár,et al.  Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing. , 2019, Clinical chemistry.

[8]  S. Vermeire,et al.  Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing , 2018, Alimentary pharmacology & therapeutics.

[9]  A. Griffiths,et al.  Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis , 2018, Journal of Crohn's & colitis.

[10]  R. Eliakim,et al.  Prospective Observational Evaluation of Time‐Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study , 2018, The American Journal of Gastroenterology.

[11]  S. Vermeire,et al.  Immunogenicity of biologics in inflammatory bowel disease , 2018, Therapeutic advances in gastroenterology.

[12]  Ravy K. Vajravelu,et al.  Improved Long‐term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  T. Matsui,et al.  Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial , 2017, Alimentary pharmacology & therapeutics.

[14]  M. Wadhwa,et al.  Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab , 2017, Cytokine.

[15]  S. Vermeire,et al.  Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial , 2017, Gut.

[16]  T. Matsui,et al.  Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. , 2016, Journal of Crohn's & colitis.

[17]  E. Lázár-Molnár,et al.  Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. , 2016, Clinical chemistry.

[18]  S. Nadler,et al.  Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes , 2016, Front. Immunol..

[19]  I. Pavlov,et al.  Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[20]  E. Havrdová,et al.  Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium , 2015, Clinical and experimental immunology.

[21]  L. Peyrin-Biroulet,et al.  Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. , 2015, Journal of Crohn's & colitis.

[22]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[23]  Theo Rispens,et al.  Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity , 2015, mAbs.

[24]  A. van Leeuwen,et al.  Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. , 2015, Journal of immunological methods.

[25]  L. Aarden,et al.  The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region , 2014, Annals of the rheumatic diseases.

[26]  G. Greenberg,et al.  The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease , 2014, Gut.

[27]  U. Kopylov,et al.  The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab , 2013, Gut.

[28]  L. A. Christensen,et al.  Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial , 2013, Gut.

[29]  W. Sandborn,et al.  A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  P. Rutgeerts,et al.  Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient , 2013, The American Journal of Gastroenterology.

[31]  K. Bendtzen,et al.  Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[32]  R. Rosenfeld,et al.  Authority , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[33]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[34]  P. Rutgeerts,et al.  EDITOR’S QUIZ: GI SNAPSHOT , 2007, Gut.

[35]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[36]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[37]  D. Milov,et al.  A Short Pediatric Crohn’s Disease Activity Index for Quality Improvement and Observational Research , 2011 .